Array Biopharma (ARRY) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Array BioPharma (ARRY) PT Raised to $9 at Jefferies; Reiterates Buy
May 11, 2017 8:49 AM EDTJefferies raised its price target on Array BioPharma (NASDAQ: ARRY) to $9.00 (from $8.00) while maintaining a Buy rating. Lower 3Q reimbursement revenues of $26M from Novartis resulted in ~11% lower revenue of ~$33M (vs. ~$37M estimates).
For bini/enco in BRAFm CRC, assuming FDA... More
